Kineta gets investment for autoimmune disease drug candidate

06/7/2010 | Seattle Times, The

Kineta has received an undisclosed investment sum from the Iacocca Family Foundation to advance the development of ShK-186, its drug candidate for autoimmune diseases such as Type 1 diabetes and multiple sclerosis. The Seattle-based biotech firm plans to conduct a Phase I trial of the drug, which inhibits some of the white blood cells that activate inflammation in autoimmune conditions, later this year.

View Full Article in:

Seattle Times, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL